Moreover, mitochondrial metabolic reprogramming driven by oncogenic KRAS or p53 mutations enhances OXPHOS reliance in microsatellite-stable (MSS) CRC, which correlates with diminished response to PD-1/PD-L1 inhibitors and a “cold” tumor immune microenvironment. The gene discussed is KRAS; the disease is colorectal carcinoma.